Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 12/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 12/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17474492 | 0.92 | CHRM5 (0.62) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL1097364 | 0.89 | CHRM5 (0.62) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL12618335 | 0.89 | CHRM5 (0.52) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL1969971 | 0.89 | CHRM5 (0.54) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL3003772 | 0.88 | CHRM5 (0.48) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL12652628 | 0.87 | CHRM5 (0.57) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL12618183 | 0.86 | CHRM5 (0.52) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL18971918 | 0.85 | MEN1 (0.47) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL3982599 | 0.84 | SLC6A3 (0.53) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL3013917 | 0.83 | CHRM5 (0.55) | CHRM5CHRM1CHRM2CHRM4CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | CHRM5 2755/4885CHRM1 2342/4885CHRM2 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.